A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. The phase II trial found that over 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib.

AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada.

The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.

Experts differ on how direct job seekers should be in closing the sale. Some say candidates miss opportunities if they don’t come right out and ask for the job. Others say a hard sell doesn’t work in this situation.

According to PhRMA, there are 264 vaccines in development to prevent and treat diseases. These include infectious diseases (137), cancer (101), allergies (10), autoimmune disease (8) and Alzheimer’s disease (4).

In March, the FDA issued a Complete Response Letter for Zynquista as a treatment for type 1 diabetes.

Boston Biomedical announced it had launched an oncology research alliance with Columbia University, Harvard University and The Wistar Institute.

Here are a few ways to amplify your job search that can help you make significant progress.

In a filing with the court, Seattle Genetics claimed the right to arbitration to resolve the dispute with Daiichi Sankyo, as is required by the 2008 collaboration agreement.

AstraZeneca inked a deal with Germany-based Cheplapharm Arzneimittel GmbH to sell the commercial rights to Seroquel and Seroquel XR in the U.S. and Canada.

The end of the year is near, but don't slow down your job search. Check out the top companies who are looking for candidates like you right now!

Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2)

The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.

As we begin the final month of 2019, the U.S. Food and Drug Administration has several PDUFA dates to approve drug applications.

There are many challenges to tackling neurological diseases like Alzheimer’s, but one is the difficulty in developing drugs that can cross the blood-brain barrier. Researchers may have found a way around that problem.

In its announcement today, OncoSec said the deal is pivotal to the company’s future. It claimed that South Korea-based Alpha Holdings, which has about 15% of the company’s stock, has been making “false and misleading statements” as it urges shareholders to oppose the deal.

Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.

ASLAN announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004, which is aimed at moderate-to-severe atopic dermatitis.

Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.

IFM Therapeutics is launching its third subsidiary this year with a focus on developing next-generation small molecule immunotherapies for inflammatory diseases and cancers.